

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cutia Therapeutics

科笛集团

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2487)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2026

At the annual general meeting (the “AGM”) of Cutia Therapeutics (the “**Company**”) held on 26 June 2026, all the proposed resolutions as set out in the notice of the AGM dated 24 April 2026 were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%) ^{(Note (a))}	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended 31 December 2025.	191,608,976 (100.00%)	0 (0.00%)
2(a).	To re-elect Mr. Lu Minfang as a non-executive director of the Company.	191,608,976 (100.00%)	0 (0.00%)
2(b).	To re-elect Ms. Yang Yunxia as a non-executive director of the Company.	170,722,681 (89.10%)	20,886,295 (10.90%)
2(c).	To re-elect Mr. Chung Ming Kit as an independent non-executive director of the Company.	191,608,976 (100.00%)	0 (0.00%)
2(d).	To re-elect Mr. Zhang Zhisong as an independent non-executive director of the Company.	191,608,976 (100.00%)	0 (0.00%)
2(e).	To re-elect Mr. Ye Xiaoxiang as an independent non-executive director of the Company.	171,361,481 (89.43%)	20,247,495 (10.57%)
2(f).	To authorise the board of directors of the Company to fix the respective directors’ remuneration.	191,608,976 (100.00%)	0 (0.00%)

Ordinary Resolutions		Number of Votes (%) ^{(Note (a))}	
		For	Against
3.	To re-appoint Ernst & Young as auditor of the Company and to authorise the board of directors of the Company to fix their remuneration.	191,608,976 (100.00%)	0 (0.00%)
4.	To give a general mandate to the directors of the Company to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.	191,608,976 (100.00%)	0 (0.00%)
5.	To give a general mandate to the directors of the Company to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.	190,982,376 (99.67%)	626,600 (0.33%)
6.	To extend, conditional upon the passing of resolutions no. 4 and 5, the general mandate granted to the directors of the Company to issue, allot and deal with additional shares of the Company by the aggregate number of the share repurchased by the Company.	170,734,881 (89.11%)	20,874,095 (10.89%)

Notes:

- (a) The number and percentage of votes are based on the total number of shares of the Company voted by the shareholders of the Company at the AGM in person or by proxy.
- (b) As a majority of the votes were cast in favour of each of the ordinary resolutions nos. 1 to 6, all the ordinary resolutions at the AGM were duly passed.
- (c) As at the date of the AGM, a total of 364,730,877 shares of the Company were in issue, which included 1,362,600 treasury shares (including any treasury shares held or deposited in the Central Clearing and Settlement System) and no shares that the Company had repurchased but not yet cancelled. The aforementioned treasury shares were excluded from the total number of issued shares entitled to attend the AGM and vote on the resolutions presented at the meeting, and the Company did not exercise voting rights for such shares at the AGM. As a result, the total number of shares entitling the holder to attend the AGM and vote for or against the proposed resolutions at the meeting was 363,368,277 shares.
- (d) There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).
- (e) No shareholder of the Company was required under the Listing Rules to abstain from voting in respect of any of the proposed resolutions at the AGM.

- (f) None of the shareholders of the Company have stated their intention in the Company's circular dated 24 April 2026 to vote against or to abstain from voting on any of the resolutions at the AGM.
- (g) The Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.
- (h) All directors of the Company attended the AGM in person or by electronics means.

By order of the Board
Cutia Therapeutics
Zhang Lele
Chief Executive Officer and Executive Director

Hong Kong, 26 June 2026

As at the date of this announcement, the board of Directors comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Mr. Lu Minfang and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Zhang Zhisong and Mr. Ye Xiaoxiang as independent non-executive directors.